Navigation Links
Study explains why Alzheimer's drug is both safe and effective
Date:8/18/2010

Alzheimer's disease destroys brain cells and their connections (called synapses), causing memory loss and other cognitive problems that disrupt work, hobbies and daily life. Symptoms can be alleviated, in part, by the drug memantine (marketed in the United States as Namenda), which is currently FDA-approved to treat moderate-to-severe Alzheimer's disease and was, in part, developed by Stuart A. Lipton, M.D., Ph.D., Director of the Del E. Web Center for Neuroscience, Aging and Stem Cell Research at Sanford-Burnham Medical Research Institute (Sanford-Burnham). Memantine improves symptoms by blocking abnormal activity of glutamate, a chemical that transmits messages between nerve cells. In a study appearing August 18 in The Journal of Neuroscience, a team of investigators at Sanford-Burnham led by Dr. Lipton unravel exactly how memantine helps Alzheimer's patients without causing serious side effects.

"While memantine is partially effective in treating Alzheimer's disease, one of its major advantages is how safe and well-tolerated it is clinically," said Dr. Lipton

In treating any disease, one of the most difficult parts of designing a new drug is finding ways to maximize its beneficial effect while minimizing harmful side effects. Memantine is a particularly safe treatment for Alzheimer's disease because it dampens excessive glutamate signaling that occurs away from synapses without blocking glutamate activity at the synapses. This is important because interfering with synaptic glutamate signaling would disrupt normal brain activity.

"We showed definitively for the first time that memantine, the drug our group developed for Alzheimer's disease, works in a unique way," Dr. Lipton said. "It inhibits a protein that binds glutamate called the NMDA receptor, but predominantly blocks NMDA receptors that signal molecularly to cause neuronal injury and death. It spares the synaptic receptors that mediate normal communication between nerve cells in the brain."

This finding helps explain why the drug is so well tolerated by Alzheimer's patients and might provide hints for the development of future therapies targeting the NMDA receptor and similar cellular machinery in other diseases.

As many as 5.3 million Americans are living with Alzheimer's, currently the seventh-leading cause of death in the United States.


'/>"/>

Contact: Josh Baxt
jbaxt@sanfordburnham.org
858-795-5236
Sanford-Burnham Medical Research Institute
Source:Eurekalert

Related biology news :

1. Long-term study shows effect of climate change on animal diversity
2. £2 million study to reveal workings of dementia genes
3. New study looks to define evangelicals and how they affect polling
4. CU-Boulder study suggests air quality regulations miss key pollutants
5. Researchers study acoustic communication in deep-sea fish
6. Study reveals homeowner perceptions in fire-prone areas
7. Researchers study how pistachios may improve heart health
8. Study: urban black bears live fast, die young
9. New study indicates link between weight gains during pregnancy and dieting history
10. Study reveals specific gene in adolescent men with delinquent peers
11. Sweat it out: UH study examines ability of sweat patches to monitor bone loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 11, 2017 Crossmatch®, a globally-recognized leader ... today announced that it has been awarded a ... Activity (IARPA) to develop next-generation Presentation Attack Detection ... "Innovation has been a driving force within Crossmatch ... allow us to innovate and develop new technologies ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:9/22/2017)... Springfield, Mo. (PRWEB) , ... September 22, 2017 ... ... company, recently announced it will host a booth at premier packaging event PACK ... is hosted by the Packaging Machinery Manufacturers Institute (PMMI). , At this year’s ...
(Date:9/21/2017)... ... September 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of UAS ... His presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo Hall. ... and discuss how probiotics have shown impressive data in areas outside the gut including ...
(Date:9/21/2017)... ... 2017 , ... When a downtown Greenville portion of the ... efficient thanks to the continuing efforts of members of the Reedy River Water ... stakeholders, including officials from area counties and cities, Renewable Water Resources (ReWa), community ...
(Date:9/20/2017)... ... 2017 , ... Diversity focused business accelerator, The Refinery , announced today ... uncover the top technology-driven, women-led startups in Boston, MA, New Haven/Hamden, CT, and Newark, ... events going on that week – in Boston, it will be part of the ...
Breaking Biology Technology: